entertainment -WSS

entertainment

author：explore 2025-09-29 23:28:16 - browse：2

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Study says nonprofit hospitals fall short in charity care spending

WSS

Listen: Your guide to Wegovy's blockbuster heart study

Eliminate the waiting period for sterilization covered by Medicaid

Where are patients getting their prescriptions for GLP

Novo acquires Inversago for up to $1 billion

Who are the detained American citizens released from prison in Iran?

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Psychedelics group wrestles with new pharma identity

The history of OxyContin, told through Purdue Pharma documents

Psychedelics group wrestles with new pharma identity

Some of the ways extreme heat will change life as we know it

United colonoscopy coverage change 'may cost lives,' doctors say

CDC overhauls leadership of center that led response to Covid

The high cost of giving birth even with insurance

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Medicare details structure of new drug price negotiation program

Study says nonprofit hospitals fall short in charity care spending

hotspot

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

An innovative path out of biotech’s “valley of death”

The history of OxyContin, told through Purdue Pharma documents

Study says nonprofit hospitals fall short in charity care spending

The history of OxyContin, told through Purdue Pharma documents

Who are the detained American citizens released from prison in Iran?

focus

knowledge

focus

explore